Literature DB >> 20380488

Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.

Jian Lin1, Hui Nie, Phillip W Tucker, Krishnendu Roy.   

Abstract

Generation of early T cells by coculturing stem cells on notch-ligand-expressing OP9 stromal cells (OP9-DL1) has been widely reported. However, further differentiation of these cells into mature, antigen-specific, functional T cells, without retroviral transduction of T cell receptors (TcRs), is yet to be achieved. In the thymic niche this differentiation is controlled by the interaction of developing TcRs with major histocompatibility (MHC) molecules on stromal cells. We hypothesized that by providing exogenous antigen-specific MHC/TcR signals, stem and progenitor cells could be engineered into functional, effector T cells specific for the same antigen. Here we demonstrate that both thymus-derived immature T cells (double positive [DP]: CD4+CD8+) and mouse embryonic stem cells can be efficiently differentiated into antigen-specific CD8+ T cells using either MHC tetramers or peptide-loaded stromal cells. DP cells, following MHC/TcR signaling, retained elevated recombination activating gene-1 levels, suggesting continuing TcR gene rearrangement. Both DP and embryonic stem-cell-derived CD8+ T cells showed significant cytotoxic T lymphocytes activity against antigen-loaded target cells, indicating that these cells are functional. Such directed differentiation strategy could provide an efficient method for generating functional, antigen-specific T cells from stem cells for potential use in adoptive T cell therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20380488      PMCID: PMC2928123          DOI: 10.1089/ten.TEA.2009.0707

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  50 in total

Review 1.  Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation.

Authors:  F van Rhee; J Barrett
Journal:  Cytotherapy       Date:  2002       Impact factor: 5.414

2.  Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.

Authors:  Luzheng Liu; Ann Chahroudi; Guido Silvestri; Mary E Wernett; William J Kaiser; Jeffrey T Safrit; Akira Komoriya; John D Altman; Beverly Z Packard; Mark B Feinberg
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  T-cell development and the CD4-CD8 lineage decision.

Authors:  Ronald N Germain
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

4.  Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro.

Authors:  Thomas M Schmitt; Juan Carlos Zúñiga-Pflücker
Journal:  Immunity       Date:  2002-12       Impact factor: 31.745

5.  Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.

Authors:  P Fontaine; G Roy-Proulx; L Knafo; C Baron; D C Roy; C Perreault
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

6.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Authors:  Marcela V Maus; Anna K Thomas; Debra G B Leonard; David Allman; Kathakali Addya; Katia Schlienger; James L Riley; Carl H June
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

7.  A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.

Authors:  J L Schultze; K C Anderson; M H Gilleece; J G Gribben; L M Nadler
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

Review 8.  Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow.

Authors:  Rainer Storb
Journal:  Exp Hematol       Date:  2003-01       Impact factor: 3.084

9.  Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.

Authors:  Joanna Galea-Lauri; David Darling; Ghulam Mufti; Phillip Harrison; Farzin Farzaneh
Journal:  Cancer Immunol Immunother       Date:  2002-06-14       Impact factor: 6.968

10.  Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system.

Authors:  Tadashi Yokosuka; Kan Takase; Misao Suzuki; Yohko Nakagawa; Shinsuke Taki; Hidemi Takahashi; Takehiko Fujisawa; Hisashi Arase; Takashi Saito
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

View more
  5 in total

1.  Development of feeder-free culture systems for generation of ckit+sca1+ progenitors from mouse iPS cells.

Authors:  Jian Lin; Irina Fernandez; Krishnendu Roy
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

Review 2.  Emerging strategies for spatiotemporal control of stem cell fate and morphogenesis.

Authors:  Melissa A Kinney; Todd C McDevitt
Journal:  Trends Biotechnol       Date:  2012-12-05       Impact factor: 19.536

Review 3.  In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination.

Authors:  Michelle J Smith; Beau R Webber; Mahmood Mohtashami; Heather E Stefanski; Juan Carlos Zúñiga-Pflücker; Bruce R Blazar
Journal:  Stem Cells       Date:  2015-08-11       Impact factor: 6.277

4.  Generation of functional, antigen-specific CD8+ human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling.

Authors:  Irina Fernandez; Tracy P Ooi; Krishnendu Roy
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

Review 5.  Engineering approaches for regeneration of T lymphopoiesis.

Authors:  Kyung-Ho Roh; Krishnendu Roy
Journal:  Biomater Res       Date:  2016-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.